ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2023年03月09日 09時00分
Source:
Eisai
エーザイ、「健康経営優良法人2023 ~ホワイト500~」に認定
東京, 2023年03月09日 - (JCN Newswire) - エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、本日、経済産業省と日本健康会議より「健康経営優良法人(大規模法人部門)2023 ~ホワイト500~」に認定されましたのでお知らせします。
「健康経営優良法人認定制度」とは、地域の健康課題に即した取り組みや日本健康会議が進める健康増進の取り組みをもとに、特に優良な健康経営を実践している大企業や中小企業等の法人を顕彰する制度であり、「経営理念・方針」「組織体制」「制度・施策実行」「評価・改善」の側面で評価します。当社は全側面で業種平均を上回り、特に「従業員への浸透」(組織体制)、「生活習慣の改善」「その他の施策*」(制度・施策実行)等の項目で高い評価を受けました。本制度は2017年に開始され、当社は5回目の認定となります。
当社は、患者様と生活者の皆様の喜怒哀楽を第一義に考え、そのベネフィット向上に貢献し、世界のヘルスケアの多様なニーズを充足することを企業理念と定め、これを「ヒューマン・ヘルスケア(hhc)理念」と呼んでいます。そして、社員をhhc理念を実現する重要なステークホルダーかつ大切な財産と位置づけ、「人財」と表現しています。「人財」の健康の維持・増進の取り組みは、hhc理念実現に向けた自発的な貢献意欲と高いエンゲージメントを備えた人財を輩出する基本であると考えています。2019年には「エーザイ健康宣言」を発効し、健康経営を推進しています。
当社は、今後も健康経営を推進することで、患者様と生活者の皆様への貢献ならびに企業価値向上に努めてまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2023/pdf/news202317pdf.pdf
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Honda Opens "Honda Software Studio Osaka" as New Software Development Operation
Jun 26, 2025 13:30 JST
Honda Issues "Honda ESG Report 2025"
Jun 26, 2025 13:29 JST
Fujitsu's Uvance Wayfinders consulting empowers customers to evolve business foundations leveraging data and AI
Jun 26, 2025 11:00 JST
MHI Receives Contract for Refurbishment of APM System at Singapore Changi Airport
Jun 25, 2025 14:00 JST
Special Summer Event "Tanabata Festival at Anime Tokyo Station" Feature a Public Recording of a Chat and Dramatic Reading by Voice Actors Miina Tominaga and Wataru Takagi on July 7
Jun 25, 2025 11:00 JST
Technica Zen and BSI Professional Services Japan Launch Customizable Training to Strengthen AI Governance in Japanese Companies
Jun 25, 2025 10:00 JST
Executive Appointments in Connection with the Establishment of NESIC Holdings
Jun 23, 2025 19:22 JST
Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined with DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeostasis
Jun 23, 2025 13:05 JST
CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health
Jun 20, 2025 19:06 JST
Sharp Launches A2 Size ePoster Color Electronic Paper Display
Jun 19, 2025 12:08 JST
Fujitsu unveils AI-powered presentation technology, enabling automated multilingual and customizable presentations
Jun 19, 2025 10:25 JST
ULVAC Continues Participation in "Lab-in-Fab" Project to Advance Piezoelectric MEMS Technology, Now Entering a New Phase
Jun 19, 2025 09:30 JST
NEC and Chugai Pharmaceutical use AI to potentially enhance cancer treatment
Jun 18, 2025 13:40 JST
Fujitsu awarded contract to design next-generation flagship supercomputer FugakuNEXT
Jun 18, 2025 11:35 JST
Honda Celebrates 60th Anniversary of First F1 Victory with Special Events Program
Jun 17, 2025 17:45 JST
MHI Receives Order to Supply 5 Models of Pumps, a Total of 34 Units, for Sizewell C Unit 1 and 2 in the UK from Trillium Flow Technologies
Jun 17, 2025 17:10 JST
Honda Teams to Compete in 2025 FIM Endurance World Championship "Coca-Cola" Suzuka 8 Hours Endurance Road Race 46th Tournament
Jun 16, 2025 16:37 JST
Fujitsu unveils Millimeter-Wave Monitoring System for enhanced safety and privacy in care facilities
Jun 16, 2025 16:20 JST
Tat Hong Equipment Service Co., Ltd. Announces 2024/25 Annual Results
Jun 13, 2025 22:49 JST
Yee Hop Holdings (1662.HK) Subsidiary APEL Launches Microfactory in Collaboration with HKPC
Jun 13, 2025 21:38 JST
More Latest Release >>
Related Release
Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan
6/2/2025 5:46:00 PM JST
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China
5/28/2025 5:45:00 PM JST
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025
5/21/2025 3:00:00 PM JST
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro
5/16/2025 5:21:00 PM JST
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star
4/30/2025 2:17:00 PM JST
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
4/18/2025 4:52:00 PM JST
Eisai to Divest Rights for Pariet in China to Peak Pharma
4/1/2025 1:15:00 PM JST
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards
3/25/2025 5:28:00 PM JST
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace
3/25/2025 12:21:00 PM JST
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
3/10/2025 8:24:00 PM JST
More Press release >>